This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): MK-3814, Adenosine 2a Receptor Antagonist, SCH 420814
Description: The adenosine 2a receptor antagonist blocks a neuromodulatory receptor that, in the brain, is almost exclusively found on dopamine D2 receptor–bearing striatopallidal neurons. These neurons secrete the neurotransmitter GABA and have an inhibitory effect. It is thought that the reduction in dopamine seen in Parkinson's disease leads to overactivity in these neurons. The adenosine 2a receptor blockade enhances the effects of dopamine on these neurons, thereby suppressing their inhibitory output.
Deal Structure: Preladenant was originally developed by Schering-Plough.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.
Additional information available to subscribers only: